L3VLUP
ProSign in

ZTS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ZTSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ZTS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterZTSJNJ
Q3 202027 holders, $13.3bn30 holders, $26.2bn
Q4 202025 holders, $13.7bn32 holders, $26.6bn
Q1 202130 holders, $13.9bn31 holders, $25.3bn
Q2 202128 holders, $15.8bn37 holders, $25.6bn
Q3 202129 holders, $16.6bn40 holders, $24.1bn
Q4 202129 holders, $21.1bn33 holders, $25.2bn
Q1 202236 holders, $17.0bn35 holders, $28.2bn
Q2 202237 holders, $15.4bn33 holders, $26.9bn
Q3 202237 holders, $12.9bn36 holders, $25.4bn
Q4 202230 holders, $12.0bn35 holders, $27.6bn
Q1 202324 holders, $13.3bn42 holders, $24.5bn
Q2 202326 holders, $13.3bn38 holders, $25.0bn
Q3 202323 holders, $13.2bn37 holders, $18.9bn
Q4 202319 holders, $14.5bn31 holders, $19.0bn
Q1 202435 holders, $12.2bn32 holders, $19.7bn
Q2 202424 holders, $10.1bn35 holders, $20.4bn
Q3 202424 holders, $9.8bn28 holders, $22.3bn
Q4 202427 holders, $7.7bn37 holders, $20.4bn
Q1 202528 holders, $7.2bn32 holders, $20.5bn
Q2 202526 holders, $6.0bn31 holders, $18.4bn
Q3 202527 holders, $5.9bn32 holders, $23.7bn
Q4 202521 holders, $5.1bn29 holders, $27.8bn
Q1 202621 holders, $4.4bn34 holders, $35.6bn
Q2 202623 holders, $2.7bn33 holders, $39.1bn
ZTS

Zoetis Inc

Holders
21
Reported value
$4.4bn
Buyers
13
Sellers
26

Breadth -13 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ZTS (7)

Baillie Gifford & Co, Caxton Associates LLP, Polen Capital Management LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Ruane Cunniff & Goldfarb LP, Voloridge Investment Management LLC

Only JNJ (20)

AQR Capital Management LLC, Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Markel Group Inc, Marshall Wace LLP, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →